Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pomalidomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 18/20 | 0.75 |
| ▸ | DDB1 known ✓ | Q16531 | 12/20 | 0.71 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.71 |
| ▸ | TNF | P01375 | 2/20 | 0.71 |
| ▸ | IL1B | P01584 | 2/20 | 0.71 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.71 |
| ▸ | BRD4 | O60885 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pomalidomide SCHEMBL7399087 | 0.91 | CRBN (0.62) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL501751 | 0.87 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL29440001 | 0.87 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL20234431 | 0.87 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL29287817 | 0.85 | CRBN (0.83) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL369172 | 0.84 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL563317 | 0.84 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL15930065 | 0.84 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL15930059 | 0.84 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL931134 | 0.84 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143420-A1 | administering immunomodulatory compounds; sickle cell anemia or beta -thalassemia; 4-(Amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione; 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione | SIGNAL PHARMACEUTICALS, LLC | 2005-06-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143420-A1 | administering immunomodulatory compounds; sickle cell anemia or beta -thalassemia; 4-(Amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione; 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione | HBG1, HBG2, CD47 | CRBN 2697/4885DDB1 62/4885IKZF3 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.